-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $80

Benzinga·01/06/2026 15:27:08
語音播報
Morgan Stanley analyst Jeffrey Hung maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the price target from $77 to $80.